We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
TOX high mobility group box family member 3 rs3803662 and breast cancer risk: A meta-analysis.
- Authors
Li, Lin; Guo, Guangcheng; Wang, Fang; Lv, Pengwei; Zhu, Mingzhi; Gu, Yuanting; Han, Mingli; Pei, Xinhong
- Abstract
<bold>Aims: </bold>Some studies suggested that TOX high mobility group box family member 3 (TOX3) rs3803662 polymorphism was associated with the risk of breast cancer. However, the results were controversy. Therefore, in order to derive a more comprehensive estimation of the association between TOX3 rs3803662 polymorphism and breast cancer risk, we conducted a meta-analysis to investigate this relationship.<bold>Materials and Methods: </bold>An electronic literature search was conducted using the following database: PubMed, EMBASE, and China National Knowledge Infrastructure till to March 31, 2015. The strength of the associations between the TOX3 rs3803662 polymorphism and breast cancer risk in per alle model was measured by odds ratios (ORs) and 95% confidence intervals (CIs).<bold>Results: </bold>A statistically significant association between TOX3 rs3803662 polymorphism and breast cancer risk was fond. The data showed that TOX3 rs3803662 polymorphism could increase the risk of breast cancer (OR = 1.20; 95% CI: 1.16-1.25; P < 0.00001). In the subgroup analysis of race, Caucasians, Asians, and Hispanics also showed increased breast cancer risk (OR = 1.21; 95% CI: 1.17-1.25; P < 0.00001; OR = 1.20; 95% CI: 1.08-1.33; P = 0.0004; OR = 1.32; 95% CI: 1.12-1.57; P = 0.001). However, African-Americans with TOX3 rs3803662 polymorphism showed decreased breast cancer risk (OR = 0.95; 95% CI: 0.86-1.04; P = 0.28), although the result was not significant. When considered estrogen receptor (ER) status, we found that ER + subjects and ER - subjects all had increased breast cancer risk, if they carried this polymorphism (OR = 1.27; 95% CI: 1.19-1.35; P < 0.00001; OR = 1.12; 95%CI: 1.08-1.17; P < 0.00001). Similarly, both progesterone receptor-positive (PR +) subjects and PR - subjects all showed increased breast cancer risk, if they carried this polymorphism (OR = 1.32; 95% CI: 1.17-1.49; P < 0.00001; OR = 1.15; 95% CI: 1.09-1.23; P < 0.00001).<bold>Conclusions: </bold>This meta-analysis suggested that TOX3 rs3803662 polymorphism was associated with increased breast cancer risk.
- Subjects
BREAST cancer risk factors; GENETIC polymorphisms; ALLELES; PROGESTERONE receptors; ESTROGEN receptors; BREAST tumors; CELL receptors; COMPARATIVE studies; DISEASE susceptibility; GENETIC techniques; RESEARCH methodology; MEDICAL cooperation; META-analysis; RESEARCH; RISK assessment; EVALUATION research; CASE-control method; PUBLICATION bias; ODDS ratio; GENOTYPES
- Publication
Journal of Cancer Research & Therapeutics, 2018, Vol 14, pS208
- ISSN
0973-1482
- Publication type
journal article
- DOI
10.4103/0973-1482.167611